U.S. Restraint vs. Iran: Strategic Caution or Strategic Shift?

At a Pentagon briefing yesterday, following Iran's attacks on the United Arab Emirates, the chairman of the Joint Chiefs of Staff told reporters that Iran's actions were "below the threshold of restarting major combat operations."

This statement reflects a deliberate restraint by the U.S., suggesting an intent to manage shipping vessels in the Strait of Hormuz without escalating into full-scale conflict, despite Iran's provocations. Iran's foreign minister responded by warning, "The U.S. should be wary of being dragged back into a quagmire by ill-wishers" and added, "so should the UAE."

The New York Times framed this restraint as delusional, publishing an article titled "White House Insists Iran War Is Over, Even While Missiles Fly." The piece, written by David E. Sanger, suggested that defense officials were choosing not to respond with maximum force to Iran's provocations. It also noted, "The White House is turning to rhetorical leaps as President Trump tries to put the biggest political crisis of his presidency behind him."

President Donald Trump had previously stated that any blockade of the Strait of Hormuz would be considered a violation of the ceasefire. However, geopolitical realities often defy binary interpretations, and such statements may also serve as negotiating tactics. It is notable that Trump has begun to distance himself from some of his initial objectives, such as regime change, and the administration appears opposed to entering a prolonged conflict.

As this analysis was being drafted, Trump took to social media, tweeting: "President Trump says Iran must agree to give up 'what has been agreed to,' or 'the bombing starts.'" (Trey Yingst, May 6, 2026)

Meanwhile, a new front in the 'war on drugs' has emerged under Health Secretary Robert F. Kennedy Jr. Unlike traditional targets, his focus is on selective serotonin reuptake inhibitors (SSRIs) such as Zoloft, Lexapro, and Prozac. Kennedy announced federal initiatives yesterday aimed at reducing the prescription of these medications.

Current data shows that about one in six American adults takes SSRIs. Women across all age groups are more likely than men to use these medications. Usage has increased in recent years, rising from approximately 13% (2015–2018) to just over 16% today.

A 2011 review found that the rate of SSRI use among both teens and adults increased by nearly 400% between 1988–1994 and 2005–2008. This upward trend has continued since then.

Speaking at a summit on mental health and overmedicalization, Kennedy stated, "Psychiatric medications have a role in care, but we will no longer treat them as the default. We will treat them as one option, to be used when appropriate, with full transparency and with a clear path off when they are no longer needed."

Kennedy also highlighted side effects associated with SSRIs, many of which have long been reported by users.